Michael DuPont
Papers
1
Total Citations
8
H-Index
1
About
Michael DuPont is a leading researcher in targeted cancer therapeutics, with a primary focus on bladder urothelial carcinoma and innovative drug delivery systems. His work centers on exploiting tumor acidity as a biomarker, particularly through the use of pH Low Insertion Peptides (pHLIPs)—a technology that senses low pH at tumor cell surfaces to enable precise intracellular delivery of therapeutic and imaging agents. In his highly cited 2022 study, DuPont demonstrated the dual application of pHLIP-ICG for imaging and pHLIP-amanitin for inhibiting urothelial cancer cell proliferation, marking a significant advance in the field. This work, which has garnered 8 citations, showcases his ability to bridge basic biophysical insights with translational oncology. DuPont’s contributions are notable for their potential to improve specificity and reduce off-target effects in cancer treatment, positioning him as an emerging authority in pH-responsive nanomedicine. His research continues to inspire new strategies for targeting metabolically active tumors, offering hope for more effective, less toxic therapies for bladder cancer patients.
Research Focus
Key Achievements
Top Papers
- 1